Shares of Minerva Neurosciences Inc. (NASDAQ:NERV) were up 7.3% during trading on Monday . The company traded as high as $11.91 and last traded at $11.56, with a volume of 699,086 shares trading hands. The stock had previously closed at $10.77.

NERV has been the subject of several analyst reports. JMP Securities increased their price target on shares of Minerva Neurosciences from $10.00 to $17.00 in a research note on Thursday, May 26th. Zacks Investment Research cut shares of Minerva Neurosciences from a “buy” rating to a “sell” rating in a research note on Wednesday, June 1st. Finally, Jefferies Group initiated coverage on shares of Minerva Neurosciences in a research note on Thursday, May 12th. They issued a “buy” rating and a $10.00 price target for the company.

The firm’s 50 day moving average is $10.59 and its 200-day moving average is $7.10. The stock’s market capitalization is $324.41 million.

Minerva Neurosciences (NASDAQ:NERV) last posted its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. Equities analysts forecast that Minerva Neurosciences Inc. will post ($1.05) earnings per share for the current year.

In related news, Director David Kupfer purchased 55,635 shares of Minerva Neurosciences stock in a transaction dated Tuesday, June 21st. The stock was acquired at an average cost of $10.84 per share, with a total value of $603,083.40. Following the completion of the transaction, the director now directly owns 209,188 shares of the company’s stock, valued at $2,267,597.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio include MIN-101 for the treatment of schizophrenia; MIN-117 for the treatment of major depressive disorder (MDD); MIN-202 (also known as JNJ-42847922) for the treatment of insomnia disorder and adjunctive MDD, and MIN-301 for the treatment of Parkinson’s disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.